Structural basis for coreceptor selectivity by the HIV type 1 V3 loop

AIDS Research and Human Retroviruses

Volumn 23, Issue 3, 2007, Pages 415-426

  Cardozo, Timothy ^a   Kimura, Tetsuya ^a   Philpott, Sean ^b   Weiser, Barbara ^b   Burger, Harold ^b   Zolla Pazner, Susan ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WADSWORTH CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120;

AMINO ACID SEQUENCE; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; RECEPTOR BINDING; SEQUENCE HOMOLOGY; VIRUS ENVELOPE;

CHEMOKINES, CC; CHEMOKINES, CXC; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; PEPTIDE FRAGMENTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34247214426     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0130     Document Type: Article

References (83)

1. Labrosse B, Treboute C, Brelot A, and Alizon M: Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. J Virol 2001;75:5457-5464.
2. Cormier EG and Dragic T: The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol 2002;76:8953-8957.
3. Fouchier RA, Groenink M, Kootstra NA, et al.: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-3187.
4. De Jong J, Simon F, Van der Groen G, et al.: V3 loop sequence analysis of seven HIV type 1 group O isolates phenotyped in peripheral blood mononuclear cells and MT-2 cells. AIDS Res Hum Retroviruses 1996;12:1503-1507.
5. Hwang SS, Boyle TJ, Lyerly HK, and Cullen BR: Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991;253:71-74.
6. De Jong JJ, De Ronde A, Keulen W, Tersmette M, and Goudsmit J: Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino acid substitution. J Virol 1992;66: 6777-6780.
7. Shioda T, Levy JA, and Cheng-Mayer C: Macrophage and T cell line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 1991;349:167-169.
8. Xiao L, Owen SM, Goldman I, et al.: CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: Delineation of consensus motif in the V3 domain that predicts CCR-5 usage. Virology 1998;240:83-92.
9. Blaak H, van't Wout AB, Brouwer M, et al.: In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc Natl Acad Sci USA 2000;97: 1269-1274.
10. Berger EA: And the best picture is - the HIV gp120 envelope, please! Nat Struct Biol 1998;5:671-674.
11. Ho SH, Shek L, Gertie A, Blanchard J, and Cheng-Mayer C: V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques. J Virol 2005;79:12296-12303.
12. Chiou SH, Freed EO, Panganiban AT, and Kenealy WR: Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function. AIDS Res Hum Retroviruses 1992;8:1611-1618.
13. Cao J, Sullivan N, Desjardin E, et al.: Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 1997;71:9808-9812.
14. Yang ZY, Chakrabarti BK, Xu L, et al.: Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. J Virol 2004;78: 4029-4036.
15. Yonezawa A, Hori T, Takaori-Kondo A, Morita R, and Uchiyama T: Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1. J Virol 2001;75:4258-4267.
16. Zolla-Pazner S: Identifying epitopes of HIV-1 that induce protective antibodies. Nature Rev Immunol 2004;4:199-210.
17. Smith AD, Geisler SC, Chen AA, et al.: Human rhinovirus type 14: Human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1. J Virol 1998;72:651-659.
18. Keller PM, Arnold BA, Shaw AR, et al.: Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. Virology 1993;193:709-716.
19. Rini JM, Stanfield RL, Stura EA, et al.: Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. Proc Natl Acad Sci USA 1993;90:6325-6329.
20. Ghiara JB, Ferguson DC, Satterthwait AC, Dyson HJ, and Wilson IA: Structure-based design of a constrained-peptide mimic of the HTV-1 V3 loop neutralization site. J Mol Biol 1997;266:31-39.
21. Stanfield RL, Ghiara JB, Ollmann Saphire E, Profy AT, and Wilson IA: Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop. Virology 2003;315:159-173.
22. Stanfield R, Cabezas E, Satterthwait A, et al.: Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs. Structure Fold Des 1999;7:131-142.
23. Weliky DP, Bennett AE, Zvi A, et al.: Solid-state NMR evidence for an antibody-dependent conformation of the V3 loop of HIV-1 gp120. Nat Struct Biol 1999;6:141-145.
24. Tugarinov V, Zvi A, Levy R, et al.: NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding. Struct Fold Des 2000;8:385-395.
25. Sharon M, Kessler N, Levy R, et al.: Alternative conformations of HIV-1 V3 loops mimic B hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure 2003;11:225-236.
26. Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, and Wilson IA: Structural rationale for the broad neutralization of HIV-1 by human antibody 447-52D. Structure 2004;12:193-204.
27. Tugarinov V, Zvi A, Levy R, and Anglister J: A cis proline turn linking two beta-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide. Nat Struct Biol 1999;6:331-335.
28. Zvi A, Tugarinov V, Faiman GA, Horovitz A, and Anglister J: A model of a gp120 V3 peptide in complex with an HIV-neutralizing antibody based on NMR and mutant cycle-derived constraints. Eur J Biochem 2000;267:767-779.
29. Rosen O, Chill J, Sharon M, et al.: Induced fit in HIV-neutralizing antibody complexes: Evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization. Biochemistry 2005;44:7250-7258.
30. Stanfield RL, Gorny MK, Zolla-Pazner S, and Wilson IA: Crystal structures of HIV-1 neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J Virol 2006;80:6093-6095.
31. White-Scharf ME, Potts BJ, Smith LM, et al.: Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization. Virology 1993;192:197-206.
32. Gorny MK, Conley AJ, Karwowska S, et al.: Neutralization of diverse HIV-1 variants by an anti-V3 human monoclonal antibody. J Virol 1992;66:7538-7542.
33. Gorny MK, Revesz K, Williams C, et al.: The V3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol 2004;78:2394-2404.
34. Sharon M, Rosen O, and Anglister J: NMR studies of V3 peptide complexes with antibodies suggest a mechanism for HIV-1 co-receptor selectivity. Curr Opin Drug Discov Dev 2005;8:601-612.
35. Milich L, Margolin B, and Swanstrom R: V3 loop of the human immunodeficiency virus type 1 Env protein: Interpreting sequence variability. J Virol 1993;67:5623-5634.
36. Resch W, Hoffman N, and Swanstrom R: Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001;288:51-62.
37. Briggs DR, Tuttle DL, Sleasman JW, and Goodenow MM: Enve-lope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). AIDS 2000;14:2937-2939.
38. Tersmette M, Gruters RA, de Wolf F, et al.: Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates. J Virol 1989;63:2118-2125.
39. Zhong P, Burda S, Konings F, et al.: Genetic and biologic properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: Further evidence of broad HIV-1 genetic diversity. AIDS Res Hum Rertroviruses 2003;19: 1167-1178.
40. Fenyo EM, Morfeldt-Manson L, Chiodi F, et al.: Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol 1988;62:4414-4419.
41. Ohnishi Y, Senda T, Nandhagopal N, et al.: Crystal structure of recombinant native SDF-1alpha with additional mutagenesis studies: An attempt at a more comprehensive interpretation of accumulated structure-activity relationship data. J Interferon Cytokine Res 2000;20:691-700.
42. Shaw JP, Johnson Z, Borlat F, et al.: The X-ray structure of RANTES: Heparin-derived disaccharides allows the rational design of chemokine inhibitors. Structure 2004;12:2081-2093.
43. Fang G, Burger H, Grimson R, et al.: Maternal plasma human immunodeficiency virus type 1 RNA level: A determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995;92:12100-12104.
44. Fang G, Weiser B, Kuiken C, et al.: Recombination following superinfection by HIV-1. AIDS 2004;18:153-159.
45. Philpott S, Weiser B, Anastos K, et al.: Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 2001;107:431-438.
46. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med 1997;185:621-628.
47. Singh A and Collman RG: Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies. J Virol 2000;74:10229-10235.
48. Philpott S, Burger H, Tsoukas C, et al.: Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: Compartmentalization and intrapatient recombination. J Virol 2005;79:353-363.
49. Brown BK, Darden JM, Tovanabutra S, et al.: Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J Virol 2005;79:6089-6101.
50. Holm-Hansen C, Stern B, Rustad S, Shao J, and Asjo B: V3 sequence analysis and biological characterization of HIV-1 isolates from asymptomatic and early symptomatic Tanzanian individuals. APMIS 2000;108:608-616.
51. Li M, Gao F, Mascola JR, et al.: Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005;79:10108-10125.
52. Lusso P, Earl PL, Sironi F, et al.: Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J Virol 2005;79:6957-6968.
53. Thompson DA, Cormier EG, and Dragic T: CCR5 and CXCR4 usage by non-clade B human immunodeficiency virus type 1 primary isolates. J Virol 2002;76:3059-3064.
54. Troyer RM, Collins KR, Abraha A, et al.: Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 2005;79:9006-9018.
55. Zuker M and Somorjai RL: The alignment of protein structures in three dimensions. Bull Math Biol 1989;51:55-78.
56. May AC and Johnson MS: Protein structure comparisons using a combination of a genetic algorithm, dynamic programming and least-squares minimization. Protein Eng 1994;7:475-485.
57. Diederichs K: Structural superposition of proteins with unknown alignment and detection of topological similarity using a six-dimensional search algorithm. Proteins 1995;23:187-195.
58. Lackner P, Koppensteiner WA, Sippl MJ, and Domingues FS: ProSup: A refined tool for protein structure alignment. Protein Eng 2000;13:745-752.
59. Abagyan RA, Totrov MM, and Kuznetsov DA: ICM: A new method for protein modeling and design: Applications to docking ahd structure prediction from the distorted native conformation. J Comp Chem 1994;15:488-506.
60. Holm L and Sander C: Protein structure comparison by alignment of distance matrices. J Mol Biol 1993;233:123-138.
61. Feng Y, Broder CC, Kennedy PE, and Berger EA: HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-877.
62. Lodi PJ, Garrett DS, Kuszewski J, et al.: High-resolution solution structure of the beta chemokine hMIP-1 beta by multidimensional NMR. Science 1994;263:1762-1767.
63. Crump MP, Gong JH, Loetscher P, et al.: Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 1997;16:6996-7007.
64. Totrov M and Abagyan R: Rapid boundary element solvation electrostatics calculations in folding simulations: Successful folding of a 23-residue peptide. Biopolymers 2001;60:124-133.
65. Borchert TV, Abagyan R, Jaenicke R, and Wierenga RK: Design, creation, and characterization of a stable, monomelic triosephosphate isomerase. Proc Natl Acad Sci USA 1994;91:1515-1518.
66. Borchert TV, Kishan KV, Zeelen JP, et al.: Three new crystal structures of point mutation variants of monoTIM: Conformational flexibility of loop-1, loop-4 and loop-8. Structure 1995;3:669-679.
67. Abagyan R and Totrov M: High-throughput docking for lead generation. Curr Opin Chem Biol 2001;5:375-382.
68. Fernandez-Recio J, Abagyan R, and Totrov M: Improving CAPRI predictions: Optimized desolvation for rigid-body docking. Proteins 2005;60:308-313.
69. Fernandez-Recio J, Totrov M, and Abagyan R: ICM-DISCO docking by global energy optimization with fully flexible side-chains. Proteins 2003;52:113-117.
70. Maiorov V and Sheridan RP: Enhanced virtual screening by combined use of two docking methods: Getting the most on a limited budget. J Chem Inf Model 2005;45:1017-1023.
71. Abagyan R: Protein structure prediction by global energy optimization. In: Computer Simulation of Biomolecular Systems: Theoretical and Experimental Applications (van Gunsteren WF, et al., eds.), Vol. 3. Springer-Verlag, Berlin, 1997, pp. 363-394.
72. Needleman SB and Wunsch CD: A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol 1970;48:443-453.
73. Rosen O, Samson A, Sharon M, Zolla-Pazner S, and Anglister J: Response to matters arising. Structure 2006;14:649-651.
74. Scheib H, Sperisen P, and Hartley O: HIV-1 coreceptor selectivity: Structural analogy between HIV-1 V3 regions and chemokine beta-hairpins is not the explanation. Structure 2006;14:645-647; discussion 649-651.
75. Kwong PD, Wyatt R, Robinson J, et al.: Structure of an HTV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-659.
76. Kwong PD, Wyatt R, Majeed S, et al.: Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Struct Fold Des 2000;8:1329-1339.
77. Huang CC, Tang M, Zhang MY, et al.: Structure of a V3-containing HIV-1 gp120 core. Science 2005;310:1025-1028.
78. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, Walker JM, and Swanstrom R: Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol 2002;76:3852-3864.
79. Koito A, Stamatatos L, and Cheng-Mayer C: Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120. Virology 1995;206:878-884.
80. Moore JP and Sodroski J: Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996;70:1863-1872.
81. Pastore C, Ramos A, and Mosier DE: Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching. J Virol 2004;78:7565-7574.
82. Yi Y, Shaheen F, and Collman RG: Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes. J Virol 2005;79:1480-1486.
83. Pastore C, Nedellec R, Ramos A, et al.: Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 2006;80: 750-758.